Etanercept biosimilar (Sunshine Guojian)

依那西普生物类似药 (三生国健)

Report date: 2023/04/03 15:32:06

Base Information

Drug NameEtanercept biosimilar (Sunshine Guojian)
Drug Alias Name依那西普生物仿制药 (Shanghai CP Guojian Pharmaceutical)Reumatocept重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 (Shanghai CP Guojian Pharmaceutical)YisaipuEtacept +[8] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor βTumor necrosis factor α
Therapy Area/IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Global Approved IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Approved Indications in ChinaPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Original Approved Country/TerritoryMainland China
Original Approved Date2005/06/20
Country/TerritoryBrazilMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Xipula Pharmaceutical Co LtdSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCipla LtdSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesEms
Active IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Inactive IndicationsN/A

Other Information

ATC CodeL04AB01
Related LinksN/A